Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
NCT05937152 · Mayo Clinic · PHASE2 · withdrawn · last registry update 2025-03-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no participants enrolled” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-27Results posted on the registry: Beth Israel Deaconess Medical Center, Fremanezumab Prefilled Syringe [Ajovy] (NCT04693533)
- 2026-02-27Also stopped (terminated): Beth Israel Deaconess Medical Center, Fremanezumab Prefilled Syringe [Ajovy] (NCT04693533)
- 2026-02-02Results posted on the registry: Duke University, Galcanezumab (NCT04158752)
- 2025-12-19Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04464707)
- 2025-12-04Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT05452239)
- 2025-09-24Phase 3 first posted: Sunnybrook Health Sciences Centre, Eptinezumab (NCT07191145)
- 2025-04-16Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04458857)
- 2025-01-31Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT05458011)
- 2024-12-10Results posted on the registry: University of California, San Francisco, Galcanezumab Prefilled Syringe + Placebo (NCT04417361)
- 2024-08-09Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04688775)
- 2024-08-06Results posted on the registry: H. Lundbeck A/S, Eptinezumab (NCT05064397)
- 2024-06-18Results posted on the registry: Eli Lilly and Company, Galcanezumab + Rimegepant (NCT05127486)
- 2024-05-29Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-05-29Also stopped (terminated): H. Lundbeck A/S, Eptinezumab + Erenumab (NCT05284019)
- 2024-05-24Phase 3 first posted: Dr George Medvedev, Eptinezumab (NCT06428838)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision